Expert Interview
Discussing Esperion's Nexletol for treating heterozygous familial hypercholesterolemia, following March 4 results.
Ticker(s): ESPRAn Cardiologist with experience in treating heterozygous familial hypercholesterolemia
Please describe your practice as a clinician, how many patients with heterozygous familial hypercholesterolemia do you see on a yearly basis? Could you walk us through the standard of care and take us through the most promising upcoming treatments, or interesting clinical trials in this space?
Please tell us about Nexletol’s mechanism of action in treating heterozygous familial hypercholesterolemia?
What are the main benefits of Nexletol for patients with heterozygous familial hypercholesterolemia?
How is Nexletol different from other medications used to treat hypercholesterolemia?
How could Nexletol impact other health conditions or medications?
How do you evaluate the LDL-C Lowering Ability of Nexletol vs Statins, and Reducing Hard Ischemic Events?
What are the benefits of NEXLETOL compared to PCSK9 inhibitors?
NEXLETOL significantly reduced the risk of hard MACE-4 and MACE-3 by 13% and 15%, respectively, and reduced the risk of heart attack and coronary revascularization by 23% and 19%. Could you please comment on those results?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
